The neurofibromatosis type 1 market remains niche, but awareness campaigns, increased diagnoses, and treatment adoption, along with ongoing clinical ...

Pasithea Therapeutics has announced the start of a Phase I/Ib open-label trial of macrocyclic mitogen-activated protein ...

Panelists discuss how mutations in the NF1 gene lead to loss of neurofibromin function, resulting in hyperactivation of the RAS/MAPK and PI3K/AKT/mTOR pathways, and how this molecular ...

Neurofibromatosis type 1 (NF1) is the most common of the three types of neurofibromatosis ... Because there is currently no cure or treatment for NF1 that can reverse or prevent complications, medical ...

Pasithea Therapeutics initiates Phase 1/1b trial of PAS-004 for neurofibromatosis type 1 ... potentially expanding treatment options for patients. Eligibility for an Australian R&D Tax Incentive ...

Panelists discuss how neurofibromatosis type 1 (NF1) is typically diagnosed in early childhood using National Institutes of ...

Additional Gross Proceeds of Approximately $1.3 Million Received Upon Exercise of Certain Warrants Issued in the Public ...

These cases only rarely progress to a point requiring treatment. All children with NF1 should have annual, comprehensive eye exams to insure early diagnosis of optic glioma. Some of the physical ...